MAO inhibitors (MAOIs): all 125 studies that test it

Page 1 of 2. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Safinamide vs Placebo for Pain in Patients With Parkinson's Disease and Motor FluctuationsRecruitingNCT07761936Phase 3
• Precision Care for Major Depressive DisorderEnrolling by invitationNCT06580041Phase 4
• Study of Harmine in Healthy SubjectsCompletedNCT05526430Phase 1Results posted
• A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South KoreaCompletedNCT05312632Phase 4Results posted
• A Single and Multiple Dose Study to Assess How the Drug Enters, Moves Through and Exits the Body, Safety and Tolerability of Safinamide in Healthy Adult Chinese VolunteersCompletedNCT03887221Phase 1Results posted
• A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of LevodopaCompletedNCT03881371Phase 3Results posted
• Effect of Safinamide on Parkinson's Disease Related Chronic PainCompletedNCT03841604Phase 4Results posted
• Safinamide for Multiple System Atrophy (MSA)CompletedNCT03753763Phase 2Results posted
• A Phase 3 Study With P2B001 in Subjects With Early Parkinson'sCompletedNCT03329508Phase 3Results posted
• Image Parkinson's Disease Progression StudyCompletedNCT02789020Phase 2Results posted
• Rasagiline Rescue in Alzheimer's Disease Clinical TrialCompletedNCT02359552Phase 2Results posted
• A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease ParticipantsCompletedNCT02337764Phase 3Results posted
• A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease ParticipantsCompletedNCT02337751Phase 3Results posted
• A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease ParticipantsCompletedNCT02337738Phase 2/3Results posted
• A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease PatientsCompletedNCT02337725Phase 3Results posted
• I2PETHV - Imidazoline2 Binding Site in Healthy VolunteersCompletedNCT02323217Early Phase 1Results posted
• Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate CancerCompletedNCT02217709Phase 2Results posted
• Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female SmokersCompletedNCT01926626Phase 2Results posted
• Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT01786603Phase 2Results posted
• Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's DiseaseCompletedNCT01723228Phase 4Results posted
• Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in ChinaCompletedNCT01556165Phase 3Results posted
• Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in ChinaCompletedNCT01479530Phase 3Results posted
• Tranylcypromine Treatment of Bipolar DepressionCompletedNCT01430455Phase 4Results posted
• Selegiline Patch for Treatment of Nicotine DependenceCompletedNCT01330030Phase 2Results posted
• Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in KoreaCompletedNCT01268891Phase 3Results posted
• Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With DocetaxelTerminatedNCT01253642Phase 2Results posted
• Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT01232738Phase 2Results posted
• Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's DiseaseCompletedNCT01168596Phase 4Results posted
• Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's DiseaseCompletedNCT01049984Phase 4Results posted
• PET Biomarkers in Treatment Resistant DepressionTerminatedNCT01031810Phase 4Results posted
• Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)CompletedNCT00977665Phase 2Results posted
• Selegiline to Zelapar Switch Study in Parkinson Disease PatientsCompletedNCT00640159Phase 4Results posted
• A Pilot Study Assessing EmSam in Bipolar DepressionTerminatedNCT00535262Phase 4Results posted
• Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major DepressionCompletedNCT00531947Phase 4Results posted
• Rasagiline in the Treatment of Persistent Negative Symptoms of SchizophreniaCompletedNCT00492336Phase 4Results posted
• Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine AgonistsCompletedNCT00443872Phase 4Results posted
• Selegiline for Smoking Cessation - 1CompletedNCT00439413Phase 2Results posted
• A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's DiseaseCompletedNCT00256204Phase 3Results posted
• Usefulness of Selegiline as an Aid to Quit Smoking - 1CompletedNCT00129311Phase 2Results posted
• Effect of Rasagiline on Balance in Parkinson's Disease as Measured by Computerized PosturographyWithdrawnNCT07077187Phase 4
• The Effect of Tranexamic Acid in Endoscopic and Microscopic Ear Surgery Cases on Surgeon SatisfactionCompletedNCT06434636Not applicable
• Molecular Imaging Study of Harmine/DMT: a Basic Research ApproachCompletedNCT06252506Phase 1
• Pharmacokinetic Profile of Betahistine With and Without Selegiline in Healthy VolunteersCompletedNCT05938517Phase 1
• Mindfulness and PsychedelicsCompletedNCT05780216Early Phase 1
• Efficacy and Safety of Rasagiline in Prodromal Parkinson's DiseaseWithdrawnNCT05611372Phase 2/3
• Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult ParticipantsCompletedNCT04978298Phase 1
• Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's DiseaseCompletedNCT04870372Phase 4
• Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy SubjectsCompletedNCT04716335Early Phase 1
• Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate AdenocarcinomaStatus unknownNCT04586543Phase 2
• Selegiline and Reward ProcessingStatus unknownNCT04130087Not applicable
• Safinamide for Levodopa-induced Dyskinesia (PD-LID)WithdrawnNCT03987750Phase 3
• Effect of Safinamide on Sleep Quality in Patients With Parkinson's DiseaseTerminatedNCT03968744Phase 4
• Overnight Switch From Rasagiline To SafinamideCompletedNCT03843944Phase 4
• An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast CancerCompletedNCT03505528Phase 1
• Safinamide Steady State Interaction With RosuvastatinCompletedNCT03216304Phase 1
• Establishment of Cessation Therapy by Clinical Trials for Subjects With Betel-quid Dependence and Oral Pre-cancerTerminatedNCT03010761Phase 2
• Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)Status unknownNCT02717884Phase 1/2
• Pharmacovigilance in Gerontopsychiatric PatientsTerminatedNCT02374567Phase 3
• Study of TCP-ATRA for Adult Patients With AML and MDSCompletedNCT02273102Phase 1
• Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is PossibleStatus unknownNCT02261779Phase 1/2
• Sagene 2014 - Parkinson's Disease and Erectile DysfunctionStatus unknownNCT02225548Phase 4
• Ambulosono Rasagiline Musical Walking StudyStatus unknownNCT02207387Not applicable
• A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc IntervalCompletedNCT02104648Phase 1
• Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal DetachmentTerminatedNCT02068625Phase 4
• Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality DisorderCompletedNCT01912391Phase 3
• A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of RasagilineCompletedNCT01879748Phase 1
• Study of Rasagiline in Patients With Amyotrophic Lateral SclerosisCompletedNCT01879241Phase 2
• Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center StudyStatus unknownNCT01765257Phase 4
• Clinical Trial of Rasagiline in Levodopa-Treated Parkinson's Disease Patients With Motor FluctuationsCompletedNCT01736891Phase 3
• A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy VolunteersCompletedNCT01701089Phase 1
• A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease TherapyCompletedNCT01677754Phase 2
• Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and WomenCompletedNCT01652313Phase 1
• A Single Dose Study of Radiolabeled RO4602522 in Healthy VolunteersCompletedNCT01631422Phase 1
• A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic TherapyCompletedNCT01497652Phase 4
• Combined Donepezil and Selegiline Effects on Cocaine-Reinforced BehaviorCompletedNCT01495195Phase 2
• Effects of Rasagiline on Sleep Disturbances in Parkinson's DiseaseCompletedNCT01442610Phase 4
• Emotion, Mood and Executive Function in Parkinson's Disease (PD)Status unknownNCT01385735Phase 4
• The Effect of Rasagiline on Cognition in Parkinson's DiseaseCompletedNCT01382342Phase 4
• Safinamide Renal Impairment TrialCompletedNCT01374113Phase 1
• 18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PDCompletedNCT01286935Phase 3
• A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain ImagingTerminatedNCT01264861Phase 2
• A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's DiseaseCompletedNCT01211587Phase 2
• Safety and Efficacy of Rasagiline in Restless Legs SyndromeTerminatedNCT01192503Phase 2/3
• Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's DiseaseCompletedNCT01187966Phase 3
• Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear PalsyTerminatedNCT01187888Phase 3
• Multicenter Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's DiseaseTerminatedNCT01178047Phase 4
• Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease SubjectsCompletedNCT01113320Phase 2
• Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOnCompletedNCT01055379Phase 4
• Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's DiseaseTerminatedNCT01048229Phase 4
• A Study to Assess the Effect of Hepatic Impairment on Safinamide PharmacokineticsCompletedNCT01027169Phase 1
• A Study to Assess the Effect of Safinamide on Levodopa PharmacokineticsCompletedNCT01026428Phase 1/2
• A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's PatientsStatus unknownNCT01007630Phase 4
• Olfaction in Patients With Parkinson's Disease Following Treatment With RasagilineCompletedNCT00902941Phase 4
• Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease PatientsTerminatedNCT00865579Phase 3
• Rasagiline and Apathy in Parkinson's DiseaseCompletedNCT00755027Phase 4
• Phase II Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation.CompletedNCT00738595Phase 2
• The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's DiseaseStatus unknownNCT00696215Phase 4
• Bioavailability Study of Tranylcypromine 10mg Tablets Under Fasting ConditionsCompletedNCT00653393Phase 1
• Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine AgonistCompletedNCT00643045Phase 3
• Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)CompletedNCT00642889Phase 3

← MAO inhibitors (MAOIs) overview